CL2018001210A1 - Compuestos de criptoficina novedosos y productos conjugados, su preparación y su uso terapéutico. - Google Patents
Compuestos de criptoficina novedosos y productos conjugados, su preparación y su uso terapéutico.Info
- Publication number
- CL2018001210A1 CL2018001210A1 CL2018001210A CL2018001210A CL2018001210A1 CL 2018001210 A1 CL2018001210 A1 CL 2018001210A1 CL 2018001210 A CL2018001210 A CL 2018001210A CL 2018001210 A CL2018001210 A CL 2018001210A CL 2018001210 A1 CL2018001210 A1 CL 2018001210A1
- Authority
- CL
- Chile
- Prior art keywords
- preparation
- therapeutic use
- conjugated products
- cryptophycin compounds
- novel cryptophycin
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Plural Heterocyclic Compounds (AREA)
- Bedding Items (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP15306751 | 2015-11-05 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CL2018001210A1 true CL2018001210A1 (es) | 2018-08-17 |
Family
ID=54476881
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2018001210A CL2018001210A1 (es) | 2015-11-05 | 2018-05-04 | Compuestos de criptoficina novedosos y productos conjugados, su preparación y su uso terapéutico. |
Country Status (35)
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10780091B2 (en) | 2016-02-05 | 2020-09-22 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | TLR7 agonist maleate salt, crystalline forms C, D and E thereof, preparation methods and uses of maleate salt and crystalline forms |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI714661B (zh) * | 2015-11-05 | 2021-01-01 | 法商賽諾菲公司 | 新穎念珠藻素化合物及接合物、其製備與其治療用途 |
| TN2019000303A1 (en) * | 2017-05-10 | 2021-05-07 | Sanofi Sa | Peptidic linkers and cryptophycin conjugates, useful in therapy, and their preparation |
| CN108107103B (zh) * | 2017-12-14 | 2020-10-16 | 华中师范大学 | 谷氨酸受体的质谱探针及其在脑组织中的空间分布规律检测方法 |
| ES2988904T3 (es) | 2019-03-07 | 2024-11-22 | Nobo Medicine Inc | Inhibidores de caspasa y métodos de utilización de los mismos |
| US11530204B2 (en) | 2019-09-30 | 2022-12-20 | The Regents Of The University Of Michigan | Biocatalytic synthesis of cryptophycin anticancer agents |
| EP4046996A1 (en) | 2021-02-19 | 2022-08-24 | Universität Bielefeld | Cryptophycin compounds and conjugates thereof |
| KR20240150807A (ko) | 2022-02-22 | 2024-10-16 | 아라리스 바이오테크 아게 | 2개 이상의 페이로드를 포함하는 펩티드 링커 |
| EP4495105A1 (en) | 2023-07-17 | 2025-01-22 | Basf Se | 3-(4-hydroxybut-2-ynoxy)propanoic acid ester, amide and nitrile derivatives as corrosion protection agents |
| EP4495108A1 (en) | 2023-07-17 | 2025-01-22 | Basf Se | 3-[2-(2-oxo-1,3-dioxolan-4-ylidene)ethoxy]propanoic acid derivatives as precursors of monomers in polymerisations |
| WO2025082990A1 (en) | 2023-10-15 | 2025-04-24 | Araris Biotech Ag | Antibody-drug conjugates using two different types of topoisomerase i inhibitors |
| WO2026013234A1 (en) | 2024-07-10 | 2026-01-15 | Araris Biotech Ag | Triple-payload antibody-drug conjugates (adcs) |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH09510436A (ja) * | 1993-12-21 | 1997-10-21 | ユニバーシティー オブ ハワイ | 新規なクリプトフィシン類 |
| US20020128185A1 (en) * | 1998-02-25 | 2002-09-12 | Chuan Shih | Pharmaceutical compounds |
| US7230101B1 (en) | 2002-08-28 | 2007-06-12 | Gpc Biotech, Inc. | Synthesis of methotrexate-containing heterodimeric molecules |
| US20050175619A1 (en) | 2004-02-05 | 2005-08-11 | Robert Duffy | Methods of producing antibody conjugates |
| US8212083B2 (en) | 2006-04-27 | 2012-07-03 | Intezyne Technologies, Inc. | Heterobifunctional poly(ethylene glycol) containing acid-labile amino protecting groups and uses thereof |
| MX2009000709A (es) | 2006-07-18 | 2009-02-04 | Sanofi Aventis | Anticuerpo antagonista contra epha2 para el tratamiento de cancer. |
| FR2947269B1 (fr) * | 2009-06-29 | 2013-01-18 | Sanofi Aventis | Nouveaux composes anticancereux |
| UY32914A (es) | 2009-10-02 | 2011-04-29 | Sanofi Aventis | Anticuerpos que se usan específicamente al receptor epha2 |
| TWI714661B (zh) * | 2015-11-05 | 2021-01-01 | 法商賽諾菲公司 | 新穎念珠藻素化合物及接合物、其製備與其治療用途 |
-
2016
- 2016-11-02 TW TW105135522A patent/TWI714661B/zh active
- 2016-11-03 WO PCT/EP2016/076603 patent/WO2017076998A1/en not_active Ceased
- 2016-11-03 US US15/768,792 patent/US10941139B2/en active Active
- 2016-11-03 MY MYPI2018701424A patent/MY189448A/en unknown
- 2016-11-03 EP EP16791017.3A patent/EP3371179B1/en active Active
- 2016-11-03 TN TNP/2018/000131A patent/TN2018000131A1/en unknown
- 2016-11-03 JP JP2018541548A patent/JP6929292B2/ja active Active
- 2016-11-03 PT PT167910173T patent/PT3371179T/pt unknown
- 2016-11-03 ES ES16791017T patent/ES2755101T3/es active Active
- 2016-11-03 EA EA201890898A patent/EA035625B1/ru not_active IP Right Cessation
- 2016-11-03 CR CR20180256A patent/CR20180256A/es unknown
- 2016-11-03 HU HUE16791017A patent/HUE046033T2/hu unknown
- 2016-11-03 MA MA43160A patent/MA43160B1/fr unknown
- 2016-11-03 PL PL16791017T patent/PL3371179T3/pl unknown
- 2016-11-03 SI SI201630418T patent/SI3371179T1/sl unknown
- 2016-11-03 HR HRP20191729 patent/HRP20191729T1/hr unknown
- 2016-11-03 HK HK18115834.8A patent/HK1256754B/en unknown
- 2016-11-03 CN CN201680064372.8A patent/CN108349960B/zh active Active
- 2016-11-03 CA CA3003085A patent/CA3003085A1/en active Pending
- 2016-11-03 MX MX2018005379A patent/MX374535B/es active IP Right Grant
- 2016-11-03 RS RS20191429A patent/RS59498B1/sr unknown
- 2016-11-03 KR KR1020187015447A patent/KR102822076B1/ko active Active
- 2016-11-03 LT LT16791017T patent/LT3371179T/lt unknown
- 2016-11-03 SG SG11201803181SA patent/SG11201803181SA/en unknown
- 2016-11-03 AU AU2016347724A patent/AU2016347724B2/en active Active
- 2016-11-03 DK DK16791017T patent/DK3371179T3/da active
- 2016-11-04 UY UY0001036979A patent/UY36979A/es not_active Application Discontinuation
- 2016-11-04 AR ARP160103379A patent/AR106604A1/es not_active Application Discontinuation
-
2018
- 2018-04-10 ZA ZA2018/02322A patent/ZA201802322B/en unknown
- 2018-04-20 PH PH12018500852A patent/PH12018500852B1/en unknown
- 2018-04-27 CO CONC2018/0004581A patent/CO2018004581A2/es unknown
- 2018-05-01 IL IL259067A patent/IL259067B/en unknown
- 2018-05-03 EC ECIEPI201834035A patent/ECSP18034035A/es unknown
- 2018-05-04 CL CL2018001210A patent/CL2018001210A1/es unknown
-
2019
- 2019-11-06 CY CY20191101166T patent/CY1122441T1/el unknown
-
2020
- 2020-12-10 US US17/118,204 patent/US20210163458A1/en not_active Abandoned
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10780091B2 (en) | 2016-02-05 | 2020-09-22 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | TLR7 agonist maleate salt, crystalline forms C, D and E thereof, preparation methods and uses of maleate salt and crystalline forms |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2018001210A1 (es) | Compuestos de criptoficina novedosos y productos conjugados, su preparación y su uso terapéutico. | |
| SV2018005794A (es) | Derivados de carbonucleósidos sustituidos útiles como agentes antineoplásicos | |
| SV2017005514A (es) | Derivados de nucleósidos sustituidos útiles como agentes antineoplásicos | |
| PY1909256A (es) | Derivados de tetrahidroquinazolina útiles como agentes anticáncer | |
| ECSP17081744A (es) | Nuevos derivados hidroxiéster,un proceso para su preparación y composiciones farmacéuticas que los contienen | |
| DOP2015000054A (es) | Derivados de c17-alcandiilo y alquendiilo del ácido oleanólico y sus métodos de uso | |
| DOP2017000298A (es) | Reguladores de nrf2 | |
| DOP2015000270A (es) | Potenciador de inhibidores del homólogo de zeste | |
| CO7210068A1 (es) | Nuevos derivados tienopirimidina, un proceso para su preparación y composiciones farmacéuticas que los contienen | |
| SV2018005760A (es) | Derivados de aminotiazol utiles como agentes antiviricos | |
| CU20140095A7 (es) | Nuevos derivados fosfatos, su procedimiento de preparación y las composiciones farmacéuticas que los contienen | |
| MX2017007377A (es) | Compuestos organicos. | |
| UY31871A (es) | Compuestos que comprenden un grupo ciclobutoxi | |
| BR112016018418A2 (pt) | Composto, uso do mesmo, e composição farmacêutica | |
| UY37348A (es) | Agentes antibacterianos de 2-pirrolidin fenilhidrazidas | |
| UY38217A (es) | Derivados de 1-imidazotiadiazol-2h-pirrol-5-ona | |
| PY1735113A (es) | Derivados de carbonucleósidos sustituidos útiles como agentes antineoplásicos |